Welcome to our dedicated page for Adaptive Biotechnologies Corporation news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies Corporation stock.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) is a commercial-stage biotechnology company dedicated to leveraging the intricate biology of the adaptive immune system to innovate in the diagnosis and treatment of diseases. The company's proprietary immune medicine platform combines high-throughput sequencing with cutting-edge computational infrastructure to offer detailed analyses of T- and B-cell repertoires, critical elements in the body's immune response. Adaptive focuses on two primary business areas: Minimal Residual Disease (MRD) and Immune Medicine.
One of Adaptive's flagship products is clonoSEQ®, a highly sensitive and standardized test authorized by the FDA for detecting minimal residual disease (MRD) in patients with multiple myeloma (MM), B-cell acute lymphoblastic leukemia (B-ALL), and chronic lymphocytic leukemia (CLL). The clonoSEQ test is also available as a CLIA-validated laboratory developed test (LDT) for other lymphoid cancers, such as diffuse large B-cell lymphoma (DLBCL). The MRD status measured by clonoSEQ serves as a powerful predictor of patient outcomes, aiding in personalized treatment and monitoring strategies.
Adaptive Biotechnologies has formed strategic partnerships with leading biopharmaceutical companies. For instance, it collaborates with Genentech on T-cell receptor (TCR) based therapeutic products, providing a neoantigen-specific T-cell receptor identified using Adaptive's TCR discovery platform. The company also signed a multi-year collaboration with BeiGene to use clonoSEQ technology in developing novel therapies for lymphoid malignancies.
In terms of financial achievements, for the year ended December 31, 2023, Adaptive reported a total revenue of $170.3 million, with the MRD revenue contributing significantly to this growth. The company achieved substantial progress in clonoSEQ test volume and introduced strategic updates to maximize the value of its MRD and Immune Medicine businesses.
Adaptive Biotechnologies operates from biotech hubs in Seattle, Washington, and South San Francisco, California. Their team of world-class scientists and open, collaborative culture drive continuous innovation. The company's clinical diagnostics and pipeline developments aim to transform the clinical landscape, offering new hope for treating cancers, autoimmune disorders, and infectious diseases.
Recently, Adaptive Biotechnologies announced significant progress and strategic decisions to enhance its business operations. They integrated clonoSEQ into Epic’s specialty diagnostics suite, easing MRD monitoring accessibility for healthcare providers. The company continues to focus on driving operational efficiencies, as reflected by a decrease in operating expenses while maintaining sustainable growth.
Adaptive Biotechnologies remains committed to leveraging the adaptive immune system's potent capabilities to develop and commercialize immune-driven clinical products tailored to individual patient needs. With a robust cash position, Adaptive aims for profitability in its MRD business while making targeted investments in Immune Medicine.
Adaptive Biotechnologies (Nasdaq: ADPT) will present data at the ASCO Annual Meeting (June 3-7, 2022) highlighting the effectiveness of its clonoSEQ assay for measuring minimal residual disease (MRD) in blood cancers. clonoSEQ is the first FDA-cleared test for MRD in chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and B-cell acute lymphoblastic leukemia (B-ALL). The data support clonoSEQ's role in assessing treatment response and patient outcomes, marking a significant step towards standardizing MRD assessment in lymphoid cancers.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) will participate in two upcoming investor conferences. The William Blair 42nd Annual Growth Stock Conference takes place on June 8 at 3:20 p.m. CT in Chicago, IL, while the Goldman Sachs 43rd Annual Global Healthcare Conference is scheduled for June 15 at 10:00 a.m. PT in Rancho Palos Verdes, CA.
Live and archived webcasts will be accessible via their website.
Adaptive Biotechnologies reported a Q1 2022 revenue of $38.6 million, a slight 0.5% increase year-over-year. The clonoSEQ test volume surged by 45% compared to Q1 2021. However, MRD revenue saw a 3% decline to $17.8 million. Operating expenses rose significantly by 28% to $101.7 million, resulting in a net loss of $62.8 million, compared to $40.6 million in Q1 2021. The company maintains its full-year revenue guidance of $185 million to $195 million.
Adaptive Biotechnologies, a biotechnology company listed on Nasdaq under the symbol ADPT, announced its participation in the BofA Securities 2022 Healthcare Conference in Las Vegas. Management will host a fireside chat on May 11 at 8:40 a.m. PT. Interested individuals can access the live and archived webcast via the company's website. Adaptive focuses on leveraging the adaptive immune system to develop clinical products for disease diagnosis and treatment, with a robust pipeline targeting cancer, autoimmune, and infectious diseases.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced it will report its first quarter 2022 financial results on May 4, 2022, after market close. The conference call is set to begin at 1:30 p.m. Pacific Time. Investors can access the live webcast on the company's website, which will also be archived for later listening. Adaptive Biotechnologies focuses on the adaptive immune system's genetics to develop diagnostics and treatments for diseases, including cancer and autoimmune conditions. The company currently has three commercial products and a strong clinical pipeline.
Adaptive Biotechnologies announces the appointment of Tycho Peterson as CFO, bringing decades of financial leadership in life sciences. This change coincides with a strategic reorganization into two areas: Minimal Residual Disease (MRD) and Immune Medicine. The MRD segment will leverage the clonoSEQ diagnostic test, while the Immune Medicine division will focus on T-cell mapping initiatives. This restructuring will involve a workforce reduction of approximately 12% and aims to enhance growth opportunities, aligning with the company's vision for future developments.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced its virtual participation in the 42nd Annual Cowen Healthcare Conference. Management will present on March 9th at 6:50 a.m. PT / 9:50 a.m. ET. The presentation will be available via a live and archived webcast on the company’s website. Adaptive Biotechnologies focuses on leveraging the adaptive immune system’s genetics to develop clinical products aimed at diagnosing and treating diseases, including cancer and autoimmune conditions. For more details, visit adaptivebiotech.com.
Adaptive Biotechnologies (ADPT) presented findings at the 17th ECCO, showcasing the use of its ImmunoSEQ® technology to identify T-cell receptors (TCRs) related to Crohn's disease (CD). The study analyzed samples from 1,738 CD patients and 4,970 healthy donors, identifying 1,121 CD-associated TCRs. These findings highlight the potential for earlier diagnosis of CD through blood tests, addressing the significant delay in symptom recognition to diagnosis. The research also explored associations between HLA alleles and CD TCRs, signaling a new avenue for understanding disease mechanisms.
Adaptive Biotechnologies reported a 57% revenue increase in 2021, reaching $154.3 million. The fourth quarter generated $37.9 million, up 26% year-over-year, with sequencing revenue soaring by 81%. Despite these gains, operating expenses rose 34% to $99.5 million, resulting in a net loss of $61.4 million for the quarter. The company's cash reserves were robust at $570.2 million as of December 31, 2021. Management is set to provide guidance for 2022 during a conference call.
Adaptive Biotechnologies (Nasdaq: ADPT) announced its participation in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16 at 12:30 p.m. PT / 3:30 p.m. ET. The company focuses on leveraging the biology of the adaptive immune system to develop clinical products for diagnosing and treating diseases, including cancer and autoimmune conditions. Adaptive has three commercial products and a robust clinical pipeline aimed at personalized medicine.
FAQ
What is the current stock price of Adaptive Biotechnologies Corporation (ADPT)?
What is the market cap of Adaptive Biotechnologies Corporation (ADPT)?
What is Adaptive Biotechnologies Corporation known for?
What is clonoSEQ?
Who are some of Adaptive Biotechnologies' key partners?
What were Adaptive Biotechnologies' financial highlights for 2023?
How does Adaptive Biotechnologies contribute to personalized medicine?
What recent strategic decisions has Adaptive Biotechnologies made?
Where are Adaptive Biotechnologies' main operations located?
What is the company culture at Adaptive Biotechnologies?
What are some key clinical applications of clonoSEQ?
What are Adaptive Biotechnologies' future goals?
